JP4855265B2 - Ｒａｓ媒介性腫瘍形成の治療のためのｒａｓ不活性化のキナーゼサプレッサー - Google Patents

Ｒａｓ媒介性腫瘍形成の治療のためのｒａｓ不活性化のキナーゼサプレッサー Download PDF

Info

Publication number
JP4855265B2
JP4855265B2 JP2006542782A JP2006542782A JP4855265B2 JP 4855265 B2 JP4855265 B2 JP 4855265B2 JP 2006542782 A JP2006542782 A JP 2006542782A JP 2006542782 A JP2006542782 A JP 2006542782A JP 4855265 B2 JP4855265 B2 JP 4855265B2
Authority
JP
Japan
Prior art keywords
ksr
ras
expression
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006542782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512844A5 (enExample
JP2007512844A (ja
Inventor
リチャード エヌ． コールズニック，
ホンメイ アール． ジン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of JP2007512844A publication Critical patent/JP2007512844A/ja
Publication of JP2007512844A5 publication Critical patent/JP2007512844A5/ja
Application granted granted Critical
Publication of JP4855265B2 publication Critical patent/JP4855265B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006542782A 2003-12-03 2004-12-03 Ｒａｓ媒介性腫瘍形成の治療のためのｒａｓ不活性化のキナーゼサプレッサー Expired - Fee Related JP4855265B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/727,358 2003-12-03
US10/727,358 US7301017B2 (en) 2002-05-30 2003-12-03 Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
PCT/US2004/040506 WO2005056756A2 (en) 2003-12-03 2004-12-03 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis

Publications (3)

Publication Number Publication Date
JP2007512844A JP2007512844A (ja) 2007-05-24
JP2007512844A5 JP2007512844A5 (enExample) 2008-01-17
JP4855265B2 true JP4855265B2 (ja) 2012-01-18

Family

ID=34677113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006542782A Expired - Fee Related JP4855265B2 (ja) 2003-12-03 2004-12-03 Ｒａｓ媒介性腫瘍形成の治療のためのｒａｓ不活性化のキナーゼサプレッサー

Country Status (8)

Country Link
US (3) US7301017B2 (enExample)
EP (1) EP1697498B1 (enExample)
JP (1) JP4855265B2 (enExample)
AT (1) ATE457351T1 (enExample)
AU (1) AU2004297594B2 (enExample)
CA (1) CA2549384A1 (enExample)
DE (1) DE602004025499D1 (enExample)
WO (1) WO2005056756A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
WO2009099507A2 (en) * 2008-01-30 2009-08-13 Duke University Treating oncogenic ras driven cancers
EP2285960B1 (en) * 2008-05-08 2015-07-08 Asuragen, INC. Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
CA2768042C (en) * 2009-07-24 2017-11-21 Universite De Montreal Bret-based biosensors and methods for monitoring raf dimerization
US8900845B2 (en) 2011-02-08 2014-12-02 Washington University Methods and uses of KSR kinase, and mutations thereof
WO2012138739A2 (en) * 2011-04-06 2012-10-11 Chemo-Enhanced Llc Compositions and methods for treating cancer
US9968570B2 (en) 2013-01-14 2018-05-15 Chemo-Enhanced Llc Compositions and methods for treating cancer
EP3901169A1 (en) * 2015-09-15 2021-10-27 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
KR101881874B1 (ko) * 2016-04-29 2018-07-26 한국수력원자력 주식회사 저선량 방사선 조사에 의한 암화 예방 방법
KR101875111B1 (ko) * 2016-04-29 2018-07-09 한국수력원자력 주식회사 저선량 방사선을 이용한 암화유전자 Ras-유도 악성 암화 억제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025144A2 (en) * 2001-09-20 2003-03-27 Isis Pharmaceuticals, Inc Antisense modulation of ksr expression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US591721A (en) 1897-10-12 Fan attachment
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6261834B1 (en) * 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
US5917122A (en) * 1992-08-26 1999-06-29 Byrne; Guerard Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic mice
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5792638A (en) * 1994-05-24 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Human ras-related oncogenes unmasked by expression cDNA cloning
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5700675A (en) 1995-12-13 1997-12-23 Regents Of The University Of California Protein kinase required for Ras signal transduction
US5786213A (en) * 1996-04-18 1998-07-28 Board Of Regents, The University Of Texas System Inhibition of endogenous gastrin expression for treatment of colorectal cancer
GB9620749D0 (en) * 1996-10-04 1996-11-20 Brax Genomics Ltd Identifying antisense oligonucleotides
JP2001505428A (ja) * 1996-12-06 2001-04-24 ニールズ パリスガード 染色体異常の検出
WO1999001139A1 (en) * 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US6849334B2 (en) 2001-08-17 2005-02-01 Neophotonics Corporation Optical materials and optical devices
GB2335035B (en) * 1998-03-03 2003-05-28 Brax Genomics Ltd Screening for functional antisense agents
WO2001047944A2 (en) * 1999-12-28 2001-07-05 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
US6329203B1 (en) * 2000-09-08 2001-12-11 Isis Pharmaceuticals, Inc. Antisense modulation of glioma-associated oncogene-1 expression
US20030051267A1 (en) * 2001-05-10 2003-03-13 Pfizer Inc. Targeted disruption of kinase suppressor of RAS
EP1513859B1 (en) * 2002-05-30 2010-07-14 Memorial Sloan-Kettering Cancer Center Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20040265961A1 (en) * 2003-03-28 2004-12-30 Wei Liu Novel proteins homologous to kinase suppressor of Ras

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025144A2 (en) * 2001-09-20 2003-03-27 Isis Pharmaceuticals, Inc Antisense modulation of ksr expression

Also Published As

Publication number Publication date
AU2004297594A1 (en) 2005-06-23
DE602004025499D1 (de) 2010-03-25
WO2005056756A2 (en) 2005-06-23
AU2004297594B2 (en) 2009-12-17
US8283459B2 (en) 2012-10-09
EP1697498A4 (en) 2007-10-31
EP1697498B1 (en) 2010-02-10
US7301017B2 (en) 2007-11-27
US20050037455A1 (en) 2005-02-17
JP2007512844A (ja) 2007-05-24
CA2549384A1 (en) 2005-06-23
ATE457351T1 (de) 2010-02-15
US20080096840A1 (en) 2008-04-24
EP1697498A2 (en) 2006-09-06
US20090143320A1 (en) 2009-06-04
US8258108B2 (en) 2012-09-04
WO2005056756A3 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
US8258108B2 (en) Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US7528116B2 (en) Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
Mercer et al. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts
Kraut et al. Requirement of the mouse I‐mfa gene for placental development and skeletal patterning
Yamamoto et al. Defective trophoblast function in mice with a targeted mutation of Ets2
Man et al. Ets2-dependent stromal regulation of mouse mammary tumors
Floyd et al. Conditional expression of the mutant Ki-ras G12C allele results in formation of benign lung adenomas: Development of a novel mouse lung tumor model
Park et al. Early embryonic lethality caused by targeted disruption of the TRAF-interacting protein (TRIP) gene
WO2011011061A2 (en) Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy
Yang et al. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame
Minowada et al. Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesis
US7642400B2 (en) Protein kinase C iota
JP2012503978A (ja) ヒトｆｇｆｒ４ａｒｇ３８８多形のための齧歯類癌モデル
KR100855355B1 (ko) Ｓｉｒｔ1 발현 억제제 함유 방사선 감수성 증진 조성물 및이를 이용하여 암세포의 방사선 감수성 증진 방법
US20130041009A1 (en) Methods and means for increasing resistance to cell damage
JP5737702B2 (ja) Ａｒｆ６遺伝子機能喪失動物及びその利用方法
JP2003506056A (ja) 腫瘍抑制遺伝子ａｎｘ７のノックアウトマウス
Man Ras/MAP kinase activation of Ets2 in development and mammary tumorigenesis
Mourez et al. Protein kinase CK2: Signaling and tumorigenesis in the mammary gland
Gowen The role of the tumor suppressor BRCA1 in murine development, cell growth, and tumorigenesis
Blackmore SHC Functions in the Development and Transformation of the Mouse Mammary Gland
Schiewer et al. Consequence of the tumor-associated conversion to cyclin D1b
Augello et al. Let us know how access to this document benefits yo u
Fiore Characterization of hERG1 channel role in the regulation of the process of neo-angiogenesis: in vitro and in vivo studies.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101019

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110506

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111014

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111026

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141104

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees